Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in Idiopathic Membranous Nephropathy
NCT04456816Phase 2Recruiting
- Sponsor
- SynAct Pharma AB
- Start
- Aug 2020
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of resomelagon in idiopathic membranous nephropathy (IMN), nephrotic syndrome, proteinuria, sponsored by SynAct Pharma AB. Started Aug 2020; status: recruiting.
02
Drugs
resomelagon
03
Conditions
idiopathic membranous nephropathy (IMN)nephrotic syndromeproteinuria
Beyond the preview
Go deeper on NCT04456816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456816.